

Optimising Patient Outcomes and Quality of Life in HR+, HER2- ABC

29 September 2019 | 13:00 – 14:30

Alicante Auditorium, Hall 3, Fira Gran Via, Barcelona, Spain

CHAIR AND MODERATOR



Prof. Nadia Harbeck
Germany

FACULTY



Prof. Stephen Chia
Canada



Prof. Dame Lesley Fallowfield
UK



Prof. Yen-Shen Lu
Taiwan

LEARNING OBJECTIVES

Create awareness of patient treatment options in HR+, HER2- ABC

Discuss key advances in the role of CDK4/6i in HR+, HER2- ABC

Review recent evidence on PI3Ki landscape in HR+, HER2- ABC

AGENDA

	TOPIC	FACULTY
13:00-13:10	Welcome and Introduction	Chair: Nadia Harbeck
13:10-13:45	Perspectives on the Growing Evidence for CDK4/6 Inhibitors	Presenter: Stephen Chia Co-presenter: Dame Lesley Fallowfield All Faculty Panel
13:45-14:20	Emerging Role of Biomarker-Driven Therapy With PI3K Inhibitors	Presenter: Yen-Shen Lu Co-presenter: Dame Lesley Fallowfield All Faculty Panel
14:20-14:30	Audience Q&A	All Faculty
14:30	Closing	Chair: Nadia Harbeck

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.